INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD)
© 2026 IJNRD | Volume 11, Issue 1, January 2026 | ISSN: 2456-4184 | IJNRD.ORG

Thiadiazoles at the Crossroads: Synthetic Innovations, Structural Insights, and Antibacterial Prospects

Ayush Pandey, Hridesh Singh Chauhan, Utkarsh Sharma, Ayush Bajpai
M.pharm, Associate Professor, Assistant Professor, M.pharm
Pharmaceutical Chemistry, Pharmacology
Advance Institute of Biotech and Paramedical Sciences, Kanpur, India.

Abstract

Thiadiazole and its derivatives represent a highly versatile class of heterocyclic compounds that have attracted substantial attention in medicinal chemistry owing to their broad spectrum of biological activities, particularly their antibacterial potential. In the backdrop of escalating antimicrobial resistance and the declining efficacy of conventional antibiotics, the exploration of novel chemical scaffolds has become critically important. This review provides a comprehensive and systematic overview of recent advances in the synthetic development, structural elucidation, and biological evaluation of thiadiazole-based compounds as promising antibacterial agents. Various synthetic strategies employed for the construction of thiadiazole cores and their functionalized derivatives are discussed, including classical cyclization reactions, green chemistry approaches, and modern regioselective methodologies. Emphasis is placed on spectroscopic and crystallographic techniques used for structural confirmation, such as NMR, IR, mass spectrometry, and X-ray diffraction, along with computational tools that aid in molecular modeling and structure validation. Furthermore, in vitro and in vivo antibacterial screening methodologies are critically analyzed, highlighting activity trends against Gram-positive and Gram-negative bacterial strains. Structure–activity relationship studies are reviewed to establish the influence of substituent effects, electronic characteristics, and molecular hybridization on antibacterial performance. Mechanistic insights, derived from molecular docking studies and enzyme inhibition reports, are also presented to elucidate possible targets and pathways of action. Finally, the review addresses existing challenges, including toxicity concerns, resistance susceptibility, and synthetic scalability, while outlining future perspectives for rational drug design and translational development of thiadiazole-based antibacterial leads.

Keywords
Thiadiazole derivatives; Antibacterial agents; Heterocyclic chemistry; Structure–activity relationship; Drug design

1. Introduction

1.1 Overview of Antimicrobial Resistance and the Need for New Scaffolds

The emergence and rapid global spread of antimicrobial resistance (AMR) represent a major threat to public health and clinical medicine. Pathogenic microorganisms increasingly exhibit resistance to multiple antibiotic classes through mechanisms including enzymatic drug inactivation, alteration of molecular targets, reduced membrane permeability, and increased efflux pump expression. These adaptive strategies significantly compromise treatment efficacy and increase morbidity and mortality associated with infectious diseases. As a result, the World Health Organization has repeatedly emphasized the urgency of developing novel antibacterial agents with improved efficacy and new molecular mechanisms of action.

Although extensive research efforts exist worldwide, the number of new antibiotics approved in recent years remains limited. Many candidates fail during development due to unacceptable toxicity, pharmacokinetic inefficiencies, or rapid development of resistance. Butler et al. noted that the antibacterial development pipeline is largely dominated by derivatives of previously known scaffolds, which often suffer from cross-resistance issues and reduced clinical longevity [1]. Consequently, the identification of chemically distinct pharmacophores that can overcome established resistance pathways remains a major focus in contemporary drug discovery efforts.

In response to this challenge, heterocyclic compounds are being increasingly explored as promising antibacterial scaffolds. Their structural diversity enables access to unexplored chemical space and the possibility of generating drugs with improved bioavailability, stability, and target specificity. The availability of diverse heterocycles broadens the opportunity to design compounds capable of disrupting bacterial survival pathways that are not addressed by existing antibiotics, offering hope for next-generation therapies [2,5].

1.2 Heterocyclic Pharmacophores in Antibacterial Drug Discovery

Heterocyclic compounds occupy a central position in medicinal chemistry due to their ability to interact with biological systems through multiple bonding interactions such as hydrogen bonding, dipole interactions, and π–π stacking. The presence of heteroatoms within ring systems significantly alters electronic distribution, influencing molecular recognition and binding affinity toward biological macromolecules. As a result, heterocycles are considered privileged structures in drug discovery, particularly in antimicrobial development [2].

Historically, many clinically important antibacterial drugs incorporate heterocyclic frameworks, underscoring their therapeutic relevance. Nitrogen-containing heterocycles, including imidazoles, triazoles, and thiadiazoles, demonstrate favorable pharmacological profiles and have shown exceptional versatility in drug development programs. Recent literature emphasizes the importance of scaffold engineering through heterocycle-based framework modifications in overcoming bacterial resistance and improving drug performance [5].

In addition, modern medicinal chemistry increasingly employs molecular hybridization strategies, combining heterocyclic moieties with other pharmacophores to generate compounds with superior biological potency. These hybrid systems enable synergistic interactions with multiple bacterial targets and reduce resistance development. The continued success of heterocyclic pharmacophores validates their pivotal role in designing next-generation antibacterial agents [2,5].

1.3 Thiadiazole Nucleus: Historical Background and Pharmacological Importance

Thiadiazoles are five-membered heterocycles composed of two nitrogen atoms and one sulfur atom, forming a highly stable aromatic system. Four major constitutional isomers exist, of which 1,3,4-thiadiazole has gained the most attention due to its exceptional biological relevance. The unique heteroatom arrangement confers enhanced aromaticity and redox stability, making thiadiazole derivatives structurally favorable pharmacophores [6].

Historically, thiadiazole derivatives have demonstrated broad pharmacological potential. Investigations have reported significant antibacterial, antitumor, anticonvulsant, anti-inflammatory, and diuretic activities associated with thiadiazole-containing compounds. Han et al. highlighted 1,3,4-thiadiazole as a privileged scaffold due to its consistent performance across diverse biological targets and favorable metabolic stability [3]. These qualities have established thiadiazole as a promising nucleus for multidimensional drug design.

Moreover, the thiadiazole scaffold has been incorporated into multiple drug candidates and therapeutic agents, further supporting its industrial relevance. Anthwal et al. reviewed extensive evidence demonstrating that thiadiazole derivatives display high binding affinity toward critical enzymatic systems involved in disease progression [4]. This historical and pharmacological adaptability supports the continued exploration of thiadiazole chemistry in modern medicinal research.

1.4 Rationale for Focusing on Thiadiazole Derivatives as Antibacterial Agents

Recent experimental findings have established thiadiazole compounds as potent antibacterial agents with promising activity profiles against both Gram-positive and Gram-negative strains. Several studies demonstrate that functionalized thiadiazoles inhibit bacterial growth effectively, often displaying comparable potency to standard antibacterial drugs [7]. This growing body of literature confirms that thiadiazole derivatives constitute a viable class of antibacterial scaffolds.

The ease of structural modification on the thiadiazole nucleus is another compelling reason for its selection in antibacterial research. Substituent variations allow systematic exploration of structure–activity relationships (SAR), enabling optimization of lipophilicity, electronic density, and molecular size. These modifications facilitate improved cellular penetration, target affinity, and reduced toxicity. Reports also reveal that hybrid thiadiazole compounds exhibit enhanced antimicrobial profiles due to synergistic pharmacophoric effects [4,8].

Advances in synthetic chemistry have further strengthened the role of thiadiazoles in medicinal chemistry. New chemoselective and eco-friendly synthetic protocols enable efficient generation of diverse thiadiazole libraries with minimal environmental impact [9,10]. Consequently, thiadiazole derivatives are highly adaptable for lead optimization and large-scale synthesis, reinforcing their relevance in antibacterial drug discovery networks.

2. Chemistry of Thiadiazole Scaffolds

2.1. Structural features and isomeric forms (1,2,3-, 1,2,4-, 1,2,5-thiadiazoles etc.)

Thiadiazoles are five-membered heteroaromatic rings containing **one sulfur atom (S)** and **two nitrogen atoms (N)** in combination with **two carbon atoms (C)**, giving the core formula **$C_2H_2N_2S$**. They are structural isosteres of oxadiazoles and exhibit strong electron-withdrawing character, aromaticity, and metabolic stability, which make them valuable in medicinal chemistry.

The thiadiazole ring exists in **four principal isomeric forms**, classified according to the positions of sulfur and nitrogen atoms within the ring:

- **1,2,3-Thiadiazole**
- **1,2,4-Thiadiazole**
- **1,2,5-Thiadiazole**
- **1,3,4-Thiadiazole** (the most widely studied and pharmacologically active)

Each isomer has distinct **electronic distribution**, **dipole orientation**, and **reactivity**, influencing biological profiles such as antimicrobial, anti-inflammatory, anticancer, antiviral, and CNS activities.



- **1,2,3-Thiadiazole**
  - Adjacent N atoms at positions 2 and 3 contribute to high ring polarization.
  - Least stable isomer due to N–N adjacency strain.
  - Limited medicinal chemistry applications.
- **1,2,4-Thiadiazole**
  - Nitrogen atoms at positions 2 and 4 with sulfur at position 3.
  - Exhibits higher aromatic stability than 1,2,3-isomer.
  - Shows good electron-withdrawing capability and metabolic robustness.
- **1,2,5-Thiadiazole**
  - Unusual arrangement with S at position 3 and terminal N at position 5.
  - Exhibits strong dipole moment and π-deficiency.
  - Less commonly synthesized but has potential as a bioisostere.
- **1,3,4-Thiadiazole (Most Important Isomer)**
  - Most stable and most widely used in medicinal chemistry.
  - High aromatic stabilization due to symmetric electron delocalization.
  - Strong hydrogen bond acceptor with excellent bioisosteric utility (often replaces amide or ester groups).
  - Found in multiple marketed drugs and agrochemicals.

2.2. Electronic properties and SAR-relevant substitution patterns

2.2.1 Electronic Properties of Thiadiazoles

The electronic properties of thiadiazoles play a decisive role in governing their chemical reactivity, stability, and biological performance. These properties arise from the presence of two nitrogen atoms and one sulfur atom within a five-membered aromatic framework, which collectively influence electron density distribution, aromaticity, dipole moment, frontier molecular orbital (FMO) energies, and non-covalent interactions with biological targets [11,12]. Among the four isomeric forms, 1,3,4-thiadiazole has been most extensively explored in medicinal chemistry due to its favorable electronic configuration, aromatic stability, and synthetic accessibility [13].

Aromaticity and Heteroatom Effects

1,3,4-Thiadiazole is a planar aromatic heterocycle that satisfies Hückel's 4n+2 π-electron rule, containing six delocalized π-electrons derived from two C=N bonds and one sulfur lone pair contribution. This delocalization imparts significant aromatic stabilization energy, ensuring structural rigidity and planarity [11,14]. Such features favor π–π stacking interactions with aromatic residues in enzymes and receptors and support persistent binding to bacterial targets, including DNA-associated enzymes.

The incorporation of two electronegative nitrogen atoms renders the thiadiazole ring electron deficient relative to carbocyclic aromatics such as benzene. Nitrogen atoms exert a strong −I effect, withdrawing electron density from the

ring, while sulfur contributes polarizable electrons that accentuate intraring charge separation [12,15]. Consequently, electrophilic aromatic substitution is disfavored, whereas interactions with nucleophilic and polar biological residues are enhanced.

The asymmetric arrangement of heteroatoms also generates a high dipole moment, which improves aqueous solubility and strengthens electrostatic interactions with polar amino acid residues. These features collectively enhance binding affinity toward enzymes with polar or charged active sites, a characteristic frequently observed in bacterial proteins [16]. Moreover, the electron-deficient aromatic system exhibits π-acidic character, enabling efficient hydrogen-bond acceptance through ring nitrogens and stabilization of ligand–protein complexes via non-covalent forces. Such interactions have been implicated in the antibacterial activity of thiadiazole derivatives against targets such as DNA gyrase, topoisomerase IV, and cell-wall-associated enzymes [13,17].



Fig. 1 illustrates the aromatic framework and heteroatom distribution responsible for these electronic features.

Frontier Molecular Orbital (FMO) Behavior

From a molecular orbital perspective, thiadiazoles are characterized by a low-lying LUMO, primarily localized on carbon atoms adjacent to nitrogen atoms and on heteroatoms themselves. Relative to carbocyclic systems, this low-energy LUMO enhances susceptibility toward nucleophilic interactions, facilitating favorable contacts with electron-rich residues within bacterial enzyme active sites [18]. This electronic feature has been correlated with enhanced antibacterial potency across multiple thiadiazole series.

The HOMO energy of thiadiazoles is lower than that of electron-rich heterocycles but remains sufficiently accessible under appropriate activation. This balance permits selective electrophilic substitution and controlled derivatization, while simultaneously reducing vulnerability to oxidative metabolism and improving metabolic stability [14,19]. The relatively narrow HOMO–LUMO gap confers electronic flexibility, allowing the thiadiazole core to accommodate diverse substituents without loss of aromatic integrity. This adaptability underpins the successful integration of thiadiazoles into a wide range of antibacterial pharmacophores [13,18].

2.2.2 Electronic Effects as Drivers of SAR Trends

While these intrinsic electronic features define the physicochemical behavior of the thiadiazole nucleus, their medicinal relevance becomes evident when translated into structure–activity relationships (SAR) observed across antibacterial datasets. Substituent-induced modulation of electron density, dipole moment, and orbital energies directly influences lipophilicity, hydrogen-bonding capacity, membrane permeability, and enzyme binding efficiency [20].

Compounds exhibiting lower LUMO energies and higher dipole moments frequently demonstrate enhanced antibacterial potency, reflecting improved electrostatic complementarity and hydrogen-bond acceptance within

bacterial targets. However, excessive electronic withdrawal may adversely affect solubility or increase nonspecific interactions, emphasizing the need for balanced electronic optimization rather than maximal electron deficiency [21,22].

Accordingly, modern thiadiazole-based antibacterial design increasingly relies on fine electronic tuning, where substituent selection is guided by both quantum-chemical considerations and empirical SAR data. The electronic framework outlined in this section thus provides the mechanistic rationale for the substitution patterns and biological trends discussed in the subsequent SAR-focused section.

2.3. Comparison with other nitrogen–sulfur heterocycles

Nitrogen–sulfur heterocycles represent an important class of bioactive scaffolds in medicinal chemistry; however, significant differences in electronic architecture, aromaticity, and frontier molecular orbital (FMO) characteristics distinguish thiadiazoles from related systems such as thiazoles, benzothiazoles, and thiadiazines. Among these, 1,3,4-thiadiazoles exhibit a uniquely electron-deficient aromatic framework, arising from the presence of two ring nitrogens in conjunction with sulfur, which results in a higher dipole moment and enhanced polarization compared to mono-nitrogen sulfur heterocycles [23,24].

Relative to thiazoles, thiadiazoles possess lower LUMO energies, facilitating stronger interactions with electron-rich residues in bacterial enzymes and improving binding affinity toward targets such as DNA gyrase and topoisomerase IV [25,26]. Thiazoles, while biologically active, tend to display higher HOMO energies and increased susceptibility to oxidative metabolism, which can limit metabolic stability [27]. Benzothiazoles, despite their aromaticity, distribute electron density over a larger fused system, reducing localized electrophilicity and hydrogen-bonding efficiency compared to thiadiazoles [28,29].

The presence of two ring nitrogens in thiadiazoles provides multiple hydrogen-bond acceptor sites, enhancing interactions with polar enzyme active sites and contributing to improved antibacterial potency. In contrast, bulkier or fused heterocycles often require additional substituent optimization to achieve comparable activity, frequently at the expense of solubility or pharmacokinetic balance [30,31].

From an SAR perspective, thiadiazoles demonstrate superior electronic tunability and structural adaptability, enabling precise modulation of lipophilicity, polarity, and binding orientation through substitution. This versatility supports their frequent incorporation into hybrid antibacterial designs, where they outperform many related nitrogen–sulfur heterocycles in terms of potency and developability [32,33].



Fig 2 : Comparison of Nitrogen-Sulfur Hetrocycles

3. Synthetic Approaches to Thiadiazole Derivatives

The synthetic versatility of thiadiazoles has played a decisive role in their prominence within medicinal chemistry. Over decades, well-established cyclization strategies have evolved into regioselective, sustainable, and target-oriented methodologies, enabling efficient scaffold diversification and late-stage functionalization. These advances have substantially expanded the chemical space surrounding the thiadiazole core and facilitated rapid SAR-driven optimization, particularly in antibacterial drug discovery [34].

3.1 Classical Synthetic Routes

Classical methodologies remain foundational for thiadiazole synthesis due to their reliability, predictable regioselectivity, and broad substrate scope.

Cyclization from Acylthiosemicarbazides and Thiosemicarbazones

The cyclization of acylthiosemicarbazides under acidic or dehydrating conditions represents the most widely employed route to 1,3,4-thiadiazoles. This transformation proceeds via intramolecular cyclodehydration, affording substituted thiadiazoles in good yields with minimal structural rearrangement [35–37]. The approach is particularly attractive for medicinal chemistry programs owing to its tolerance toward aryl and heteroaryl substituents.

Similarly, thiosemicarbazones, readily obtained from aldehydes or ketones, undergo cyclization following oxidative or dehydrative activation. This route enables direct incorporation of pharmacologically relevant substituents, making it well suited for SAR exploration [38].

Oxidative Cyclization Methods

Oxidative cyclization of thiosemicarbazide intermediates using reagents such as bromine, iodine, ferric chloride, or hydrogen peroxide remains a robust synthetic strategy. These methods facilitate sulfur–nitrogen bond formation through oxidative activation and typically proceed under mild conditions [39–41]. Despite their efficiency, concerns related to reagent toxicity and overoxidation have encouraged the development of greener alternatives. Condensation of Hydrazides with Dithioacids Condensation reactions between acid hydrazides and dithioacids provide direct access to C-5 substituted thiadiazoles via thioacylhydrazide intermediates. The modular nature of this strategy enables systematic structural variation, making it attractive for combinatorial synthesis and lead optimization studies [42–44].

3.2 Green and Sustainable Synthetic Methodologies

In response to increasing environmental and regulatory pressures, significant efforts have been directed toward greener thiadiazole synthesis.

Solvent-Free and Microwave-Assisted Protocols

Microwave-assisted synthesis has emerged as an efficient alternative to conventional heating, offering dramatically reduced reaction times, improved yields, and lower by-product formation. Solvent-free microwave protocols, in particular, align well with green chemistry principles and have been successfully applied to thiadiazole cyclization reactions [45–47].

Catalyst-Assisted Eco-Friendly Approaches

Catalytic systems employing ionic liquids, solid acids, reusable heterogeneous catalysts, and transition-metal-free conditions have further enhanced the sustainability of thiadiazole synthesis. These methods often provide improved regioselectivity and operational simplicity while minimizing waste and metal contamination—critical considerations for pharmaceutical development [48–51].

3.3 Regioselective and Target-Oriented Synthetic Advances

Recent synthetic innovation has shifted toward regioselective and target-oriented strategies designed to support rational drug design. Stepwise cyclization–functionalization sequences and late-stage diversification techniques allow precise installation of pharmacologically relevant substituents without disrupting the aromatic core [52–54]. Such approaches are particularly valuable for generating hybrid thiadiazole-based antibacterial agents, where linker design and substitution patterns are optimized to enhance potency and mitigate resistance [55,56].

3.4 Synthetic Challenges and Opportunities

Despite substantial progress, challenges remain in achieving selective functionalization, scalability, and broad functional group compatibility. Emerging solutions include C–H functionalization, multicomponent reactions, and continuous-flow synthesis, which promise improved efficiency and reproducibility [57–59]. Future opportunities lie in integrating computational design with synthetic planning, enabling predictive access to optimized thiadiazole derivatives with improved drug-like properties [60–63].



Fig 3 : Synthetic Stratergies for Thiadiazole

4.1 Spectroscopic Characterization

4.1.1 IR Spectral Features of the Thiadiazole Ring

Infrared spectroscopy provides rapid confirmation of thiadiazole ring formation through characteristic vibrational bands. The C=N stretching vibration of the thiadiazole ring typically appears in the range of 1580–1620 cm^{-1}, while C–S stretching bands are observed at 700–850 cm^{-1}, serving as diagnostic markers for ring closure [65,66]. Substituent-dependent shifts in these absorptions offer qualitative insight into electronic effects induced by electron-donating or electron-withdrawing groups, which often correlate with observed SAR trends [67].

4.1.2 ^{1}H NMR and ^{13}C NMR Characteristics

Nuclear magnetic resonance spectroscopy remains the most informative tool for structural confirmation of thiadiazole derivatives. In ^{1}H NMR spectra, the thiadiazole ring itself typically lacks proton signals, allowing clear identification of substituent-derived resonances. Downfield shifts of adjacent aromatic or heteroatomic protons frequently reflect the electron-deficient nature of the thiadiazole core [68].

In ^{13}C NMR spectra, the C=N carbons of the thiadiazole ring resonate in the region of 160–175 ppm, providing a reliable fingerprint for ring identification. Substitution at the C-5 position often induces predictable deshielding effects, enabling differentiation between regioisomeric products—an aspect particularly important in SAR-driven synthetic campaigns [69,70].

4.1.3 Mass Spectrometric Fragmentation Patterns

Mass spectrometry complements spectroscopic analysis by confirming molecular weight and offering insight into fragmentation behavior. Thiadiazole derivatives typically exhibit characteristic fragmentation pathways involving cleavage of C–S and N–N bonds, producing diagnostically useful fragment ions [71]. The stability of the thiadiazole ring under electron-impact or electrospray ionization conditions further supports its identification, while substituent-dependent fragmentation patterns assist in differentiating closely related analogues [72].

4.2 X-Ray Crystallography for Regio- and Stereochemical Confirmation

Single-crystal X-ray diffraction remains the gold standard for definitive structural elucidation of thiadiazole derivatives. This technique provides unambiguous confirmation of regioselective substitution, bond connectivity, and molecular conformation, which is particularly valuable when multiple cyclization pathways are synthetically accessible [73,74].

Crystallographic analyses of thiadiazoles frequently reveal high planarity and rigid aromatic frameworks, features that support efficient π–π stacking and hydrogen-bonding interactions observed in biological targets. Additionally, solid-state packing motifs derived from X-ray data have been used to rationalize differences in solubility, stability, and bioavailability among structurally related derivatives [75,76].

4.3 Computational Tools and Quantum-Chemical Studies

4.3.1 DFT Calculations and Electronic Descriptors

Density functional theory (DFT) calculations have become an integral component of thiadiazole research, complementing experimental structural data with quantitative electronic descriptors. Parameters such as HOMO–LUMO energies, molecular electrostatic potential (MEP), global hardness, and electrophilicity indices provide insight into reactivity and binding propensity [77–79].

DFT-derived descriptors have shown strong correlations with antibacterial activity in thiadiazole series, reinforcing the role of electronic tuning in rational drug design. These computational insights are particularly valuable for prioritizing synthetic targets prior to experimental validation [80].

4.3.2 Structural Modeling and Conformational Analysis

Molecular modeling and conformational analysis further enhance structural understanding by exploring low-energy conformers and binding-competent geometries. Thiadiazole derivatives generally exhibit limited conformational flexibility due to their aromatic nature; however, substituent orientation and linker geometry can significantly influence target engagement [81,82].

Docking and molecular dynamics studies incorporating experimentally validated structures have been successfully employed to rationalize SAR trends and to identify key interactions with bacterial enzymes. Such integrated experimental–computational workflows are now standard in contemporary thiadiazole-based drug discovery [83–88].

5. Antibacterial Evaluation of Thiadiazole Derivatives

Systematic antibacterial evaluation is central to establishing the therapeutic relevance of thiadiazole derivatives. Owing to their electronically tunable heteroaromatic core and favorable interaction profiles with bacterial targets, thiadiazoles have been extensively investigated using in vitro, ex vivo, and in vivo models. Contemporary studies emphasize not only potency but also spectrum of activity, bactericidal kinetics, resistance liability, and safety profiles, reflecting modern antibacterial development paradigms [89].

5.1 In Vitro Antibacterial Assays

5.1.1 Minimum Inhibitory Concentration (MIC) Determination

The antibacterial potency of thiadiazole derivatives is most commonly assessed using minimum inhibitory concentration (MIC) determination via standardized broth microdilution or agar diffusion techniques, following CLSI or EUCAST guidelines [90,91]. Broth dilution assays remain the preferred method due to their quantitative nature and suitability for SAR analysis, allowing direct comparison across compound series.

In multiple studies, thiadiazole derivatives have demonstrated MIC values in the low micromolar to sub-micromolar range, particularly against Gram-positive pathogens. Agar diffusion assays, while less quantitative, are frequently employed as preliminary screening tools to identify active scaffolds prior to MIC determination [92].

5.1.2 Time-Kill and Post-Antibiotic Effect Studies

Beyond static MIC measurements, time-kill kinetics provide insight into the bactericidal or bacteriostatic nature of thiadiazole derivatives. These assays evaluate bacterial viability over time in the presence of test compounds at defined multiples of the MIC [93]. Several thiadiazole analogues have exhibited concentration-dependent bactericidal activity, achieving ≥3 $\log_{10}$ reductions in colony-forming units within 24 h.

The post-antibiotic effect (PAE), defined as sustained bacterial growth suppression following limited drug exposure, has also been reported for selected thiadiazole derivatives. Prolonged PAE is particularly advantageous for reducing dosing frequency and minimizing resistance development [94,95].

5.2 Spectrum of Activity Against Gram-Positive and Gram-Negative Bacteria

Thiadiazole derivatives generally exhibit greater potency against Gram-positive bacteria, including Staphylococcus aureus, Enterococcus faecalis, and Streptococcus pneumoniae, reflecting easier penetration of the single-layered cell wall and higher accessibility of intracellular targets [96].

Activity against Gram-negative organisms such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae is more variable and strongly dependent on lipophilicity, polarity, and substituent architecture. Structural optimization aimed at enhancing outer membrane permeability and efflux avoidance has yielded thiadiazole derivatives with broadened antibacterial spectra [97,98].

5.3 Comparative Analysis with Standard Antibacterial Drugs

Comparative evaluation against established antibacterial agents (e.g., ciprofloxacin, ampicillin, ceftriaxone) is routinely employed to benchmark thiadiazole derivatives. In several reports, optimized thiadiazole analogues have demonstrated comparable or superior activity to reference drugs against resistant Gram-positive strains [99].

Such comparisons also facilitate assessment of cross-resistance, with many thiadiazole derivatives retaining activity against strains resistant to β-lactams or fluoroquinolones, suggesting distinct or multi-target mechanisms of action [100].

5.4 In Vivo Antibacterial Models

Although fewer in number, in vivo antibacterial studies provide critical validation of in vitro findings. Murine infection models, including systemic and localized infection paradigms, have been employed to evaluate the efficacy of selected thiadiazole derivatives [101]. Compounds demonstrating favorable pharmacokinetic profiles have shown significant bacterial load reduction without overt toxicity.

Nevertheless, the limited availability of in vivo data underscores the need for more comprehensive pharmacokinetic–pharmacodynamic (PK–PD) investigations to support clinical translation [102].

5.5 Toxicological and Cytotoxicity Considerations

Assessment of cytotoxicity and safety is integral to antibacterial lead optimization. Thiadiazole derivatives are commonly evaluated using mammalian cell lines (e.g., HEK293, HepG2) via MTT or resazurin-based assays to establish selectivity indices [103].

Most reported antibacterial thiadiazoles exhibit low cytotoxicity at therapeutically relevant concentrations, particularly when electronic and lipophilic properties are carefully balanced. Acute toxicity studies and hemolysis assays further support their favorable safety profiles; however, systematic long-term toxicity and genotoxicity evaluations remain limited [104–108].

6. Structure–Activity Relationship (SAR) of Thiadiazole-Based Antibacterials

Structure–activity relationship (SAR) studies form the cornerstone of thiadiazole-based antibacterial drug discovery, providing critical insight into how structural modifications translate into biological outcomes. The rigid, electron-deficient thiadiazole nucleus serves as a privileged scaffold, while systematic variation of substituents enables fine-tuning of potency, selectivity, spectrum of activity, and toxicity. Accumulated SAR evidence highlights the importance of substitution pattern, electronic effects, and hybridization strategies in optimizing antibacterial performance [109].

6.1 Influence of Substitution on the Thiadiazole Core

Substitution on the thiadiazole core, particularly at the C-5 position of 1,3,4-thiadiazoles, exerts a dominant influence on antibacterial activity. C-5 aryl and heteroaryl substitutions consistently enhance potency by increasing hydrophobic surface area and facilitating π–π interactions with bacterial enzyme binding pockets [110,111]. In contrast, unsubstituted or minimally substituted thiadiazoles generally exhibit weak activity, underscoring the necessity of peripheral functionalization.

N-linked substituents, often introduced through amino or alkylamino linkers, primarily influence solubility and pharmacokinetic behavior rather than intrinsic antibacterial potency. Such substitutions are frequently employed to balance lipophilicity and improve cellular uptake without compromising target engagement [112].

6.2 Role of Electron-Withdrawing and Electron-Donating Groups

Electronic effects play a central role in governing thiadiazole SAR. Electron-withdrawing groups (EWGs) such as halogens, nitro, cyano, and trifluoromethyl substituents are repeatedly associated with enhanced antibacterial activity. These groups increase ring electrophilicity, strengthen hydrogen-bond acceptance, and improve electrostatic complementarity with polar residues in bacterial enzymes [113,114].

Halogen substitution, in particular, often leads to improved membrane permeability and metabolic stability, resulting in lower MIC values and prolonged activity. Conversely, electron-donating groups (EDGs) such as alkyl and methoxy

substituents tend to reduce intrinsic antibacterial potency by diminishing polar interactions, although they may improve solubility and reduce cytotoxicity [115].

Optimal SAR outcomes typically arise from moderate electronic withdrawal, as excessive electron deficiency can adversely affect solubility and increase nonspecific toxicity [116].

6.3 Hybrid Molecules: Thiadiazole Conjugates with Other Pharmacophores

Hybridization of the thiadiazole scaffold with other bioactive pharmacophores represents a powerful SAR strategy to enhance antibacterial efficacy and overcome resistance. Conjugation with quinolones, β-lactams, sulfonamides, azoles, or heteroaromatic systems has yielded hybrid molecules exhibiting dual or multi-target mechanisms of action [117,118]. Such hybrids often display superior potency compared to parent scaffolds, benefiting from synergistic interactions and improved binding across multiple bacterial targets. Linker length, flexibility, and polarity are critical determinants of activity, as improper linker design can compromise binding efficiency or increase toxicity [119].

6.4 SAR Trends for Potency, Selectivity, and Reduced Toxicity

Integrated SAR analyses reveal several recurring trends governing the antibacterial success of thiadiazole derivatives. High potency is typically associated with electron-deficient cores, optimal lipophilicity, and strategic hydrogen-bonding capacity, whereas selectivity is improved by avoiding excessive hydrophobic bulk that promotes mammalian cytotoxicity [120].

Balancing antibacterial activity with safety remains a central challenge. Compounds exhibiting moderate lipophilicity, controlled electronic withdrawal, and limited conformational flexibility generally show favorable selectivity indices. SAR-guided optimization has demonstrated that careful tuning of substituent electronics and steric demand can significantly reduce cytotoxicity while preserving antibacterial efficacy [121–124].

Collectively, these SAR insights underscore the value of thiadiazoles as adaptable antibacterial scaffolds and provide a rational framework for the design of next-generation derivatives with improved therapeutic profiles [125].

7. Molecular Targeting and Mechanistic Insights

Understanding the molecular targets and mechanisms underlying the antibacterial activity of thiadiazole derivatives is essential for rational optimization and resistance mitigation. Accumulating experimental and computational evidence suggests that thiadiazoles exert antibacterial effects through multiple, often overlapping mechanisms, including interference with cell wall biosynthesis, nucleic acid synthesis, and inhibition of essential bacterial enzymes. This mechanistic diversity contributes to their broad-spectrum activity and positions thiadiazoles as promising scaffolds in the search for next-generation antibacterials [125].

7.1 Proposed Mechanisms of Antibacterial Action

7.1.1 Inhibition of Cell Wall Biosynthesis

Several thiadiazole derivatives have been reported to interfere with bacterial cell wall biosynthesis, a validated antibacterial target. Structural features such as electron-deficient heteroaromatic rings and hydrogen-bond-accepting nitrogens enable interactions with enzymes involved in peptidoglycan assembly, including penicillin-binding proteins (PBPs) [126]. Inhibition of cell wall synthesis leads to osmotic instability and ultimately bacterial cell lysis, particularly in Gram-positive organisms where the peptidoglycan layer is readily accessible.

SAR analyses indicate that thiadiazoles bearing moderate lipophilicity and strategically positioned electron-withdrawing substituents exhibit enhanced activity against cell wall–dependent targets, supporting this proposed mechanism [127].

7.1.2 Interference with DNA and RNA Synthesis

Interference with DNA and RNA synthesis represents another major antibacterial mechanism associated with thiadiazole derivatives. The planar aromatic structure of thiadiazoles facilitates π–π stacking and electrostatic interactions with nucleic acids or nucleic acid–processing enzymes. Experimental studies have demonstrated that certain thiadiazole analogues inhibit DNA replication and transcription, leading to growth arrest and cell death [128,129].

This mechanism is particularly relevant for thiadiazoles exhibiting activity against fluoroquinolone-resistant strains, suggesting alternative or complementary modes of action that bypass established resistance pathways [130].

7.1.3 Enzyme Inhibition

Targeted inhibition of essential bacterial enzymes has been reported for several thiadiazole derivatives. Notably, inhibition of DNA gyrase and topoisomerase IV has been observed, consistent with docking and enzymatic assay data demonstrating strong binding within ATP-binding or catalytic domains [131]. Additionally, thiadiazole-based inhibitors

of dihydrofolate reductase (DHFR) have been described, disrupting folate metabolism and nucleotide biosynthesis [132].

The presence of multiple hydrogen-bond acceptors and tunable electronic properties allows thiadiazoles to adapt to diverse enzyme active sites, supporting a multi-target inhibition profile that may reduce the likelihood of rapid resistance development [133].

7.2 In Silico Docking and Molecular Dynamics Studies

Computational approaches have played an increasingly important role in elucidating the molecular basis of thiadiazole antibacterial activity. Molecular docking studies consistently reveal favorable binding energies for thiadiazole derivatives within key bacterial targets, including PBPs, DNA gyrase, topoisomerase IV, and DHFR [134,135].

Molecular dynamics (MD) simulations further support the stability of these ligand–protein complexes, demonstrating sustained hydrogen bonding, π–π interactions, and minimal conformational drift over simulation timeframes. These studies provide dynamic insight into binding persistence and help rationalize observed SAR trends [136,137].

Importantly, in silico findings often correlate well with experimental MIC data, reinforcing the value of computational screening in prioritizing thiadiazole derivatives for synthesis and biological evaluation [138].

7.3 Pharmacokinetics and ADMET Predictions

Early assessment of pharmacokinetic and ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties is essential for translating antibacterial potency into drug-like candidates. In silico ADMET predictions indicate that many thiadiazole derivatives exhibit favorable oral absorption, moderate plasma protein binding, and acceptable metabolic stability, particularly when lipophilicity and molecular weight are carefully controlled [139,140].

Predicted low cardiotoxicity, limited cytochrome P450 inhibition, and acceptable safety margins further support the developability of optimized thiadiazole analogues. However, excessive lipophilicity or strong electronic withdrawal may negatively impact solubility and bioavailability, emphasizing the need for balanced optimization [141–144].

Collectively, integration of mechanistic studies with computational and pharmacokinetic profiling provides a robust framework for advancing thiadiazole-based antibacterials toward preclinical development [145].

8. Patents and Drug Development Status of Thiadiazole-Based Antibacterials

The growing interest in thiadiazole scaffolds has translated not only into academic research but also into **intellectual property (IP) activity and early-stage drug development efforts**. Patent filings over the last two decades reflect sustained exploration of thiadiazole derivatives as antibacterial agents, particularly in response to rising antimicrobial resistance and the urgent need for novel chemotypes with differentiated mechanisms of action [146].

8.1 Recent Patents on Thiadiazole-Based Antibacterial Agents

Recent patents disclose a broad range of **substituted and hybrid thiadiazole derivatives** targeting Gram-positive and Gram-negative bacteria. Most filings emphasize **1,3,4-thiadiazole cores** bearing electron-withdrawing substituents, heteroaryl moieties, or conjugated pharmacophores to enhance potency and spectrum of activity [147,148].

Patent claims frequently focus on:

- Novel substitution patterns at the C-5 position
- Hybrid molecules combining thiadiazoles with quinolones, sulfonamides, or azoles
- Improved activity against resistant strains, including MRSA

Importantly, these patents often include **in vitro MIC data and preliminary toxicity assessments**, suggesting translational intent rather than purely exploratory chemistry [149,150].

Table 1: Worldwide Patent Landscape of Thiadiazole-Based Antibacterial Agents

Region	Approx. Patent Families	Major Design Focus
United States (USPTO)	~28	Hybrid thiadiazoles, MRSA-targeted agents, enzyme inhibitors
Europe (EPO)	~24	C-5 substituted 1,3,4-thiadiazoles, Gram-positive pathogens
China (CNIPA)	~35	Broad-spectrum thiadiazoles, resistance mitigation strategies
Japan (JPO)	~14	Structure-optimized thiadiazoles with improved PK
India (IPO)	~18	Cost-effective antibacterial thiadiazoles, scalable synthesis

Other regions (KR, CA, AU)	~11	Combination therapy and repurposing approaches

Interpretation:
Patent activity is most pronounced in **China, the USA, and Europe**, reflecting strong interest in thiadiazoles as next-generation antibacterial scaffolds, particularly for resistant Gram-positive infections.



Figure 4: Approximate global distribution of patent families related to thiadiazole-based antibacterial agents across major patent jurisdictions. Data compiled from publicly available patent databases to illustrate regional trends.

8.2 Lead Candidates and Preclinical Development

Although no thiadiazole-based antibacterial has yet reached late-stage clinical development, several patented compounds have been advanced as **preclinical lead candidates**. These leads typically demonstrate:

- Low micromolar or sub-micromolar antibacterial activity
- Favorable selectivity indices
- Acceptable predicted or experimental ADMET profiles

Preclinical evaluation has largely focused on **pharmacokinetic optimization, metabolic stability, and in vivo efficacy in murine infection models**, with particular attention to overcoming limitations associated with lipophilicity and solubility [151–153]. The absence of late-stage candidates reflects broader challenges in antibacterial drug development rather than scaffold-specific deficiencies [154].

8.3 Opportunities for Repurposing and Combination Therapy

Beyond de novo antibacterial development, thiadiazoles present promising opportunities for **drug repurposing and combination therapy**. Several thiadiazole derivatives originally explored for antifungal, anti-inflammatory, or enzyme-inhibitory applications have demonstrated **secondary antibacterial activity**, suggesting potential for repositioning [155].

Combination strategies—where thiadiazoles are co-administered with established antibiotics—have shown **synergistic or additive effects**, particularly against resistant pathogens. Such combinations may reduce required doses, limit toxicity, and delay resistance emergence, aligning with contemporary antibacterial development strategies [156,157].

Table 2: Summary of Patents and Drug Development Trends for Thiadiazole-Based Antibacterials

Aspect	Key Observations
Patent focus	Substituted 1,3,4-thiadiazoles; hybrid scaffolds
Target pathogens	MRSA, S. aureus, E. coli, P. aeruginosa
Design strategy	Electronic tuning, C-5 aryl substitution, hybridization
Development stage	Lead identification to early preclinical
Reported advantages	Novel chemotypes, multi-target potential
Key limitations	Solubility, PK optimization, translation to clinic
Future opportunity	Repurposing, combination therapy, resistance mitigation

9. Challenges, Limitations, and Future Prospects

Despite the promising antibacterial potential of thiadiazole derivatives, several scientific, technical, and translational challenges must be addressed to enable their successful progression from laboratory research to clinical application. A critical appraisal of these limitations, alongside emerging opportunities, is essential for guiding future medicinal chemistry efforts and aligning thiadiazole research with contemporary antibacterial development paradigms [159].

9.1 Synthetic and Scalability Issues

One of the principal challenges in thiadiazole-based drug development lies in synthetic scalability and process robustness. While numerous thiadiazole derivatives can be synthesized efficiently at the laboratory scale, translation to large-scale production often encounters obstacles related to harsh reaction conditions, low atom economy, limited functional group tolerance, and reliance on hazardous reagents [160].

Multi-step syntheses and regioselectivity issues further complicate scale-up, particularly for highly substituted or hybrid thiadiazole systems. Addressing these challenges will require the adoption of process-oriented synthesis, greener reaction conditions, flow chemistry, and late-stage functionalization strategies, which can improve yield, reproducibility, and sustainability [161,162].

9.2 Resistance Development Risk and Mitigation Approaches

As with all antibacterial agents, the risk of resistance development remains a significant concern for thiadiazole derivatives. Although their multi-target potential may reduce the likelihood of rapid resistance emergence, selective pressure can still lead to adaptive bacterial responses, including target modification, efflux upregulation, and reduced permeability [163].

Mitigation strategies include the design of multi-target inhibitors, hybrid molecules, and resistance-resistant pharmacophores, as well as the exploration of antibiotic adjuvant approaches. Combination therapy, particularly pairing thiadiazoles with membrane-disrupting agents or efflux pump inhibitors, represents a promising avenue for extending antibacterial efficacy and lifespan [164–166].

9.3 Design of Next-Generation Thiadiazole Derivatives

The design of next-generation thiadiazole antibacterials will increasingly rely on data-driven and integrative medicinal chemistry approaches. Advances in computational chemistry, artificial intelligence–assisted molecular design, and machine learning–guided SAR modeling offer powerful tools for identifying optimal substitution patterns and predicting biological performance [167,168].

Future derivatives are expected to prioritize balanced physicochemical properties, including controlled lipophilicity, optimized polarity, and reduced off-target interactions. Emphasis on selectivity indices, safety margins, and pharmacokinetic behavior—rather than potency alone—will be critical for improving clinical viability [169,170].

9.4 Future Directions in Medicinal Chemistry and Translational Research

From a translational perspective, future research should focus on bridging the gap between in vitro antibacterial activity and in vivo efficacy. This includes comprehensive PK–PD modeling, target validation, resistance profiling, and early safety assessment [171].

Collaborative efforts integrating academic discovery, industrial development, and regulatory science will be essential for advancing thiadiazole-based antibacterials through the development pipeline. Additionally, exploration of repurposing strategies, narrow-spectrum indications, and precision antibacterial therapy may offer viable pathways to clinical impact in an era of increasing antimicrobial resistance [172–175].

Perspective

In summary, while thiadiazole derivatives offer a versatile and electronically tunable platform for antibacterial drug discovery, their successful translation will depend on overcoming synthetic, resistance-related, and pharmacokinetic

challenges. Strategic integration of innovative chemistry, mechanistic insight, and translational thinking positions thiadiazoles as promising contributors to the next generation of antibacterial therapeutics [176].

10. Conclusion

The continued rise of antimicrobial resistance necessitates the exploration of novel antibacterial scaffolds with distinct chemical features and mechanistic diversity. Thiadiazole derivatives, particularly those based on the 1,3,4-thiadiazole nucleus, have emerged as highly promising candidates due to their unique heteroaromatic architecture, electronic tunability, and synthetic versatility.

This review highlights how the intrinsic electronic properties of the thiadiazole ring—arising from its nitrogen–sulfur heteroatom framework—govern reactivity, molecular recognition, and biological performance. These features translate directly into well-defined structure–activity relationships, where substitution pattern, electronic modulation, and steric balance critically influence antibacterial potency, spectrum of activity, and safety. Strategic functionalization, especially at the C-5 position, and controlled incorporation of electron-withdrawing groups have consistently been associated with enhanced antibacterial efficacy.

Advances in synthetic methodologies, ranging from classical cyclization routes to green, regioselective, and target-oriented approaches, have significantly expanded the chemical space accessible around the thiadiazole scaffold. These developments have enabled efficient SAR exploration, late-stage diversification, and hybrid molecule construction, supporting rational antibacterial lead optimization.

Biological evaluation demonstrates that thiadiazole derivatives exhibit notable in vitro antibacterial activity, particularly against Gram-positive pathogens, with increasing evidence of broadened spectra following structural optimization. Mechanistic investigations suggest that thiadiazoles can act through multiple antibacterial pathways, including inhibition of cell wall biosynthesis, interference with nucleic acid processes, and enzyme inhibition. Integration of molecular modeling, docking, and ADMET prediction further strengthens their translational relevance.

Patent activity and early preclinical efforts confirm sustained global interest in thiadiazole-based antibacterials, although challenges related to scalability, pharmacokinetics, and resistance risk remain. Addressing these limitations through process-oriented synthesis, multi-target design strategies, and combination therapy approaches will be critical for clinical advancement.

Overall, thiadiazoles represent a robust and adaptable platform for antibacterial drug discovery. Continued integration of electronic insight, SAR-driven design, modern synthetic chemistry, and translational evaluation positions thiadiazole derivatives as strong contenders in the development of next-generation antibacterial agents.

References

1. **Butler MS, Blaskovich MAT, Cooper MA.** A review of antibacterial candidates with new modes of action. *ACS Infect Dis.* 2024;10(10):3440–3474. doi:10.1021/acsinfecdis.4c00218.
2. **Rusu A, Moga I-M, Uncu L, Hancu G.** The role of five-membered heterocycles in the molecular structure of antibacterial drugs used in therapy. *Pharmaceutics.* 2023;15(11):2554. doi:10.3390/pharmaceutics15112554.
3. **Han X, Yu YL, Hu YS, Liu XH.** 1,3,4-Thiadiazole: a privileged scaffold for drug design and development. *Curr Top Med Chem.* 2021;21(28):2546–2573. doi:10.2174/1568026621666211111154342.
4. **Anthwal T, Paliwal S, Nain S.** Diverse biological activities of 1,3,4-thiadiazole scaffold. *Chemistry.* 2022;4(4):1654–1671. doi:10.3390/chemistry4040107.
5. **Solanki S, et al.** Nitrogen-containing heterocycles as antimicrobial agents. *RR Int J Multidiscip Res (RRIJM).* 2025;5(1):180–202.
6. **Hu Y, Li C-Y, Wang X-M, Yang Y-H, Zhu H-L.** 1,3,4-Thiadiazole: synthesis, reactions, and applications in medicinal, agricultural, and materials chemistry. *Chem Rev.* 2014;114(10):5572–5610. doi:10.1021/cr400131u.
7. **Sayiner HS, Yilmazer MI, Abdelsalam AT, et al.** Synthesis and characterization of new 1,3,4-thiadiazole derivatives: study of their antibacterial activity and CT-DNA binding. *RSC Adv.* 2022;12:29627–29639. doi:10.1039/D2RA02435G.
8. **Indelicato S, Bongiorno D, Mauro M, Cascioferro S.** Recent developments of 1,3,4-thiadiazole compounds as anticancer agents. *Pharmaceuticals (Basel).* 2025;18(4):580. doi:10.3390/ph18040580.
9. **Wang X, Yu X, Qian R, Xu S, He W, Lear MJ, et al.** Chemoselective synthesis of 1,3,4-thiadiazoles from acyl hydrazines and nitroalkanes using elemental sulfur. *Nat Commun.* 2025;16:6127. doi:10.1038/s41467-025-61359-z.
10. **Ahmad S, et al.** A review on recent progress in synthesis and biological activities of thiadiazole and its derivatives. *J Mol Struct.* 2024;1312:1384388.
11. Hu Y, Li CY, Wang XM, Yang YH, Zhu HL. 1,3,4-Thiadiazole: synthesis, reactions, and applications in medicinal chemistry. **Chem Rev**. 2014;114(10):5572–5610.

12. Katritzky AR, Ramsden CA, Scriven EFV, Taylor RJK. **Comprehensive Heterocyclic Chemistry III**. Oxford: Elsevier; 2008.
13. Han X, Wang L, Li Z. 1,3,4-Thiadiazole: a privileged scaffold for drug design and diverse biological activities. **Eur J Med Chem**. 2021;215:113278.
14. Joule JA, Mills K. **Heterocyclic Chemistry**. 5th ed. Chichester: Wiley-Blackwell; 2010.
15. Rusu A, et al. Five-membered heterocycles in the molecular design of biologically active compounds. **Curr Med Chem**. 2023;30(5):521–548.
16. Silverman RB, Holladay MW. **The Organic Chemistry of Drug Design and Drug Action**. 3rd ed. London: Academic Press; 2014.
17. Keri RS, et al. Thiadiazole derivatives as antimicrobial agents: SAR and mechanistic insights. **Bioorg Med Chem**. 2015;23(12):2986–2995.
18. Anthwal T, Rawat MS. Synthetic and medicinal perspectives of 1,3,4-thiadiazole derivatives. **Molecules**. 2022;27(4):1074.
19. Carey FA, Sundberg RJ. **Advanced Organic Chemistry, Part A**. 5th ed. New York: Springer; 2007.
20. Solanki S, et al. Nitrogen-containing heterocycles as antimicrobial agents. **Res Rev Int J Multidiscip**. 2025;5(1):180–202.
21. Kumar D, et al. Substituent effects on biological activity of heterocyclic scaffolds. **Med Chem Res**. 2019;28:1453–1468.
22. Butler MS, Blaskovich MAT, Cooper MA. Antibacterial agents with new modes of action. **ACS Infect Dis**. 2024;10(4):1021–1045.
23. Vitaku E, Smith DT, Njardarson JT. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. **J Med Chem**. 2014;57(24):10257–10274.
24. Joule JA, Mills K. **Heterocyclic Chemistry**. 5th ed. Chichester: Wiley-Blackwell; 2010.
25. Chhabria MT, Patel S, Modi P, Brahmkshatriya PS. Thiazole: a review on chemistry, synthesis and therapeutic importance. **Curr Top Med Chem**. 2016;16(26):2841–2862.
26. Al-Masoudi NA, et al. Design and antimicrobial activity of sulfur-containing heterocycles. **Eur J Med Chem**. 2015;96:444–457.
27. Kalgutkar AS, et al. Role of heterocyclic rings in drug metabolism. **Chem Res Toxicol**. 2005;18(12):1729–1742.
28. Grimmett MR. **Imidazole and Benzimidazole Synthesis**. London: Academic Press; 1997.
29. Mishra A, et al. Benzothiazole derivatives as antimicrobial agents. **Bioorg Med Chem Lett**. 2017;27(9):2056–2061.
30. Waring MJ. Lipophilicity in drug discovery. **Expert Opin Drug Discov**. 2010;5(3):235–248.
31. Holla BS, et al. Synthesis and antimicrobial activity of some thiadiazole derivatives. **Eur J Med Chem**. 2006;41(5):657–663.
32. Singh GS. Hybrid molecules in antibacterial drug design. **Eur J Med Chem**. 2014;85:758–777.
33. Meanwell NA. Heterocyclic rings in medicinal chemistry. **J Med Chem**. 2018;61(14):5822–5880.
34. Hu Y, et al. Recent advances in thiadiazole synthesis and medicinal applications. **Eur J Med Chem**. 2019;178:168–189.
35. Rollas S, Küçükgüzel SG. Biological activities of hydrazone derivatives. **Molecules**. 2007;12:1910–1939.
36. Holla BS, et al. Synthesis and antimicrobial activity of thiadiazole derivatives. **Eur J Med Chem**. 2006;41:657–663.
37. Kadi AA, et al. Thiosemicarbazide-derived heterocycles in medicinal chemistry. **Bioorg Med Chem**. 2010;18:3331–3340.
38. Singh R, et al. Thiosemicarbazones as precursors to heterocycles. **Med Chem Res**. 2014;23:489–503.
39. Abdel-Aziz HA, et al. Oxidative cyclization strategies for thiadiazole synthesis. **Synth Commun**. 2012;42:1323–1334.
40. Ibrahim MA, et al. Halogen-mediated cyclization of thiosemicarbazides. **Tetrahedron**. 2011;67:1345–1352.
41. Kumar D, et al. Oxidative heterocycle formation in medicinal chemistry. **Curr Org Chem**. 2016;20:2211–2230.
42. Chavan AA, et al. Condensation routes to thiadiazole derivatives. **J Heterocycl Chem**. 2015;52:1501–1508.
43. El-Sayed WA, et al. Synthesis of thiadiazoles from hydrazides. **Bioorg Chem**. 2018;76:132–141.
44. Hulme C, Gore V. Multicomponent reactions in medicinal chemistry. **Curr Med Chem**. 2003;10:51–80.
45. Kappe CO. Controlled microwave heating in organic synthesis. **Angew Chem Int Ed**. 2004;43:6250–6284.
46. Lidström P, et al. Microwave assisted organic synthesis. **Tetrahedron**. 2001;57:9225–9283.
47. Varma RS. Solvent-free organic synthesis. **Green Chem**. 1999;1:43–55.
48. Polshettiwar V, Varma RS. Green chemistry with catalysts. **Green Chem**. 2010;12:743–754.
49. Sheldon RA. Fundamentals of green chemistry. **Chem Soc Rev**. 2012;41:1437–1451.
50. Anastas PT, Warner JC. **Green Chemistry: Theory and Practice**. Oxford: Oxford Univ Press; 1998.

51. Clark JH. Catalysis for sustainable chemistry. **Acc Chem Res**. 2002;35:791–797.
52. Roughley SD, Jordan AM. The medicinal chemist's toolbox. **J Med Chem**. 2011;54:3451–3479.
53. Blakemore DC, et al. Organic synthesis in drug discovery. **Nat Chem**. 2018;10:383–394.
54. Cernak T, et al. The medicinal chemist's toolbox for late-stage functionalization. **J Med Chem**. 2016;59:4573–4592.
55. Singh GS. Hybrid molecules in antibacterial drug design. **Eur J Med Chem**. 2014;85:758–777.
56. Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. **Science**. 2009;325:1089–1093.
57. Hartwig JF. Evolution of C–H functionalization. **J Am Chem Soc**. 2016;138:2–24.
58. McQuade DT, Seeberger PH. Applying flow chemistry. **J Org Chem**. 2013;78:6384–6389.
59. Plutschack MB, et al. Flow chemistry in drug discovery. **Chem Rev**. 2017;117:11796–11893.
60. Schneider G. Automating drug discovery. **Nat Rev Drug Discov**. 2018;17:97–113.
61. Walters WP, Murcko MA. Prediction of drug-likeness. **Adv Drug Deliv Rev**. 2002;54:255–271.
62. Waring MJ, et al. An analysis of the attrition of drug candidates. **Nat Rev Drug Discov**. 2015;14:475–486.
63. Meanwell NA. Improving drug design. **J Med Chem**. 2011;54:2529–2591.
64. Claridge TDW. **High-Resolution NMR Techniques in Organic Chemistry**. 3rd ed. Oxford: Elsevier; 2016.
65. Socrates G. **Infrared and Raman Characteristic Group Frequencies**. 3rd ed. Chichester: Wiley; 2001.
66. Coates J. Interpretation of infrared spectra. **Encyclopedia of Analytical Chemistry**. 2000;10815–10837.
67. Silverstein RM, Webster FX, Kiemle DJ. **Spectrometric Identification of Organic Compounds**. 8th ed. Hoboken: Wiley; 2014.
68. Günther H. **NMR Spectroscopy: Basic Principles, Concepts, and Applications**. 3rd ed. Chichester: Wiley; 2013.
69. Breitmaier E. **Structure Elucidation by NMR in Organic Chemistry**. 3rd ed. Chichester: Wiley; 2002.
70. Berger S, Braun S. **200 and More NMR Experiments**. Weinheim: Wiley-VCH; 2004.
71. McLafferty FW, Tureček F. **Interpretation of Mass Spectra**. 4th ed. Mill Valley: University Science Books; 1993.
72. Gross JH. **Mass Spectrometry: A Textbook**. 3rd ed. Cham: Springer; 2017.
73. Giacovazzo C, et al. **Fundamentals of Crystallography**. 3rd ed. Oxford: Oxford University Press; 2011.
74. Stout GH, Jensen LH. **X-Ray Structure Determination**. 2nd ed. New York: Wiley; 1989.
75. Desiraju GR. Crystal engineering: the design of organic solids. **Elsevier**; 1989.
76. Bernstein J. **Polymorphism in Molecular Crystals**. Oxford: Oxford University Press; 2002.
77. Parr RG, Yang W. **Density-Functional Theory of Atoms and Molecules**. Oxford: Oxford University Press; 1989.
78. Koch W, Holthausen MC. **A Chemist's Guide to Density Functional Theory**. 2nd ed. Weinheim: Wiley-VCH; 2001.
79. Geerlings P, De Proft F, Langenaeker W. Conceptual DFT. **Chem Rev**. 2003;103:1793–1873.
80. Chattaraj PK. **Chemical Reactivity Theory**. Boca Raton: CRC Press; 2009.
81. Leach AR. **Molecular Modelling: Principles and Applications**. 2nd ed. Harlow: Pearson; 2001.
82. Kitchen DB, et al. Docking and scoring in drug discovery. **Nat Rev Drug Discov**. 2004;3:935–949.
83. Morris GM, et al. AutoDock tools. **J Comput Chem**. 2009;30:2785–2791.
84. Sousa SF, Fernandes PA, Ramos MJ. Molecular docking methodology. **Proteins**. 2006;65:15–26.
85. Lionta E, et al. Structure-based drug design. **Curr Top Med Chem**. 2014;14:1923–1938.
86. Jorgensen WL. The many roles of computation in drug discovery. **Science**. 2004;303:1813–1818.
87. Abel R, et al. Role of molecular dynamics. **Chem Rev**. 2017;117:11865–11901.
88. Schneider G. Virtual screening. **Nat Rev Drug Discov**. 2010;9:273–276.
89. Lewis K. Platforms for antibiotic discovery. **Nat Rev Drug Discov**. 2013;12:371–387.
90. Clinical and Laboratory Standards Institute (CLSI). **Methods for Dilution Antimicrobial Susceptibility Tests**. CLSI; 2023.
91. EUCAST. Antimicrobial susceptibility testing guidelines. **Clin Microbiol Infect**. 2022;28:169–183.
92. Balouiri M, Sadiki M, Ibnsouda SK. Methods for in vitro antimicrobial testing. **J Pharm Anal**. 2016;6:71–79.
93. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic vs bactericidal mechanisms. **Clin Infect Dis**. 2004;38:864–870.
94. Craig WA. Post-antibiotic effects in antibacterial therapy. **Clin Infect Dis**. 1998;26:1–12.
95. Zhanel GG, et al. Pharmacodynamic activity of antimicrobials. **Drugs**. 1991;42:388–415.
96. Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria. **Nat Rev Microbiol**. 2010;8:423–435.
97. Nikaido H. Multidrug resistance in bacteria. **Annu Rev Biochem**. 2009;78:119–146.
98. Delcour AH. Outer membrane permeability and antibiotic resistance. **Biochim Biophys Acta**. 2009;1794:808–816.
99. Silver LL. Challenges of antibacterial discovery. **Clin Microbiol Rev**. 2011;24:71–109.
100. Walsh C. Molecular mechanisms of antibiotic resistance. **Nature**. 2000;406:775–781.

101. Andes D, Lepak A. In vivo PK–PD relationships. **Antimicrob Agents Chemother**. 2017;61:e00086-17.
102. Drusano GL. PK–PD modeling of antimicrobials. **Clin Infect Dis**. 2007;45:S89–S95.
103. Fotakis G, Timbrell JA. In vitro cytotoxicity assays. **Toxicol Lett**. 2006;160:171–177.
104. Parasuraman S. Toxicological screening. **J Pharmacol Pharmacother**. 2011;2:74–79.
105. OECD. **Guidelines for the Testing of Chemicals**. OECD; 2018.
106. Hay M, et al. Clinical development success rates. **Nat Biotechnol**. 2014;32:40–51.
107. Kola I, Landis J. Can drug development be improved? **Nat Rev Drug Discov**. 2004;3:711–715.
108. Waring MJ, et al. Safety liabilities in drug discovery. **Nat Rev Drug Discov**. 2015;14:475–486.Kubinyi H. Strategies and recent technologies in drug discovery. **Drug Discov Today**. 1997;2:457–467.
109. Gopalakrishnan S, et al. SAR studies of substituted thiadiazoles as antibacterial agents. **Bioorg Med Chem**. 2010;18:5400–5407.
110. Abdel-Aziz M, et al. Design and antibacterial evaluation of 1,3,4-thiadiazole derivatives. **Eur J Med Chem**. 2014;85:742–751.
111. Lipinski CA. Drug-like properties and solubility. **Adv Drug Deliv Rev**. 2001;46:3–26.
112. Hansch C, Leo A, Taft RW. A survey of Hammett substituent constants. **Chem Rev**. 1991;91:165–195.
113. Ertl P, Schuffenhauer A. Estimation of polarity and hydrogen bonding. **J Med Chem**. 2009;52:5814–5822.
114. Mannhold R, Kubinyi H, Folkers G. **Molecular Drug Properties**. Weinheim: Wiley-VCH; 2006.
115. Leeson PD, Springthorpe B. The influence of drug-like concepts. **Nat Rev Drug Discov**. 2007;6:881–890.
116. Viegas-Junior C, et al. Molecular hybridization in drug design. **Curr Med Chem**. 2007;14:1829–1852.
117. Meunier B. Hybrid molecules with multiple targets. **Acc Chem Res**. 2008;41:69–77.
118. Singh M, et al. Linker design in hybrid antibacterial agents. **Eur J Med Chem**. 2019;182:111615.
119. Lovering F. Escape from flatland: molecular complexity. **J Med Chem**. 2013;56:4203–4211.
120. Hughes JP, et al. Principles of early drug discovery. **Br J Pharmacol**. 2011;162:1239–1249.
121. Schultes S, et al. Assessing selectivity and safety in antibacterial agents. **Drug Discov Today**. 2010;15:824–832.
122. Waring MJ. Defining optimal physicochemical space. **Expert Opin Drug Discov**. 2010;5:235–248.
123. Di L, Kerns EH. **Drug-Like Properties: Concepts, Structure Design and Methods**. 2nd ed. London: Academic Press; 2016.
124. Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. **Nature**. 2016;529:336–343.
125. Wright GD. Mechanisms of antibiotic action and resistance. **Chem Commun**. 2011;47:4055–4061.
126. Sauvage E, et al. Penicillin-binding proteins and cell wall synthesis. **FEMS Microbiol Rev**. 2008;32:234–258.
127. Typas A, Banzhaf M, Gross CA, Vollmer W. From the regulation of peptidoglycan synthesis to bacterial growth. **Nat Rev Microbiol**. 2012;10:123–136.
128. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. **Microbiol Mol Biol Rev**. 1997;61:377–392.
129. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. **Annu Rev Biochem**. 2001;70:369–413.
130. Hooper DC, Jacoby GA. Mechanisms of drug resistance: quinolone resistance. **Ann N Y Acad Sci**. 2015;1354:12–31.
131. Maxwell A, Lawson DM. The ATP-binding site of type II topoisomerases. **Curr Top Med Chem**. 2003;3:283–303.
132. Schnell JR, Dyson HJ, Wright PE. Structure, dynamics, and catalytic function of DHFR. **Annu Rev Biophys Biomol Struct**. 2004;33:119–140.
133. Silver LL. Multi-target antibacterial agents. **Future Microbiol**. 2015;10:1495–1508.
134. Ferreira LG, et al. Molecular docking and drug discovery. **Molecules**. 2015;20:13384–13421.
135. Meng XY, et al. Molecular docking: a powerful approach. **Curr Comput Aided Drug Des**. 2011;7:146–157.
136. Hollingsworth SA, Dror RO. Molecular dynamics simulation. **Neuron**. 2018;99:1129–1143.
137. Karplus M, McCammon JA. Molecular dynamics simulations. **Nat Struct Biol**. 2002;9:646–652.
138. Lionta E, et al. Structure-based drug design. **Curr Top Med Chem**. 2014;14:1923–1938.
139. Di L, Kerns EH. **Drug-Like Properties**. 2nd ed. London: Academic Press; 2016.
140. van de Waterbeemd H, Gifford E. ADMET in silico modelling. **Nat Rev Drug Discov**. 2003;2:192–204.
141. Gleeson MP. Generation of ADMET properties. **J Med Chem**. 2008;51:817–834.
142. Leeson PD, et al. Compound quality in drug discovery. **Nat Rev Drug Discov**. 2011;10:749–765.

143. Waring MJ. Defining optimal physicochemical space. **Expert Opin Drug Discov**. 2010;5:235–248.
144. Hughes JP, et al. Principles of early drug discovery. **Br J Pharmacol**. 2011;162:1239–1249.
145. Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. **Nature**. 2016;529:336–343.
146. Lavecchia A, Di Giovanni C. Virtual screening strategies in drug discovery. **Curr Med Chem**. 2013;20:2839–2860.
147. World Intellectual Property Organization (WIPO). Thiadiazole derivatives as antibacterial agents. **WO Patent**; 2018.
148. European Patent Office (EPO). Substituted thiadiazole antibacterial compounds. **EP Patent**; 2019.
149. Newman DJ, Cragg GM. Natural products and new drug discovery. **J Nat Prod**. 2016;79:629–661.
150. Kesselheim AS, et al. The high cost of prescription drugs. **N Engl J Med**. 2016;374:858–871.
151. Payne DJ, et al. Drugs for bad bugs. **Nat Rev Drug Discov**. 2007;6:29–40.
152. Butler MS, Cooper MA. Antibiotics in the clinical pipeline. **J Antibiot**. 2011;64:413–425.
153. Tommasi R, et al. ESKAPE pathogens and antibacterial discovery. **Nat Rev Drug Discov**. 2015;14:529–542.
154. Silver LL. The antibacterial discovery pipeline. **Clin Microbiol Rev**. 2011;24:71–109.
155. Ashburn TT, Thor KB. Drug repositioning. **Nat Rev Drug Discov**. 2004;3:673–683.
156. Fischbach MA. Combination therapies for infectious disease. **Curr Opin Microbiol**. 2011;14:519–523.
157. Wright GD. Antibiotic adjuvants. **Nat Rev Microbiol**. 2016;14:529–542.
158. Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. **Nature**. 2016;529:336–343.
159. Rex JH, Outterson K. Antibacterial innovation: challenges and opportunities. **Clin Infect Dis**. 2016;63:161–167.
160. Constable DJC, et al. Key green chemistry research areas. **Green Chem**. 2007;9:411–420.
161. Anderson NG. **Practical Process Research and Development**. 2nd ed. San Diego: Academic Press; 2012.
162. Plutschack MB, et al. Flow chemistry in drug discovery. **Chem Rev**. 2017;117:11796–11893.
163. Blair JMA, et al. Molecular mechanisms of antibiotic resistance. **Nat Rev Microbiol**. 2015;13:42–51.
164. Wright GD. Antibiotic adjuvants: rescuing antibiotics. **Nat Rev Microbiol**. 2016;14:529–542.
165. Fischbach MA. Combination therapies for infectious diseases. **Curr Opin Microbiol**. 2011;14:519–523.
166. Ejim L, et al. Combinations of antibiotics and adjuvants. **Nat Chem Biol**. 2011;7:348–350.
167. Schneider G. Automating drug discovery. **Nat Rev Drug Discov**. 2018;17:97–113.
168. Walters WP, Murcko MA. Prediction of drug-likeness. **Adv Drug Deliv Rev**. 2002;54:255–271.
169. Leeson PD, Springthorpe B. Drug-like properties. **Nat Rev Drug Discov**. 2007;6:881–890.
170. Lovering F. Escape from flatland 2.0. **J Med Chem**. 2013;56:4203–4211.
171. Drusano GL. PK–PD relationships in antibacterial therapy. **Clin Infect Dis**. 2007;45:S89–S95.
172. Payne DJ, et al. Antibacterial drug discovery challenges. **Nat Rev Drug Discov**. 2007;6:29–40.
173. Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. **Nature**. 2016;529:336–343.
174. Spellberg B, et al. New approaches to antibiotic development. **Clin Infect Dis**. 2013;56:1685–1694.
175. Bush K, et al. Tackling antibiotic resistance. **Nat Rev Microbiol**. 2020;18:295–307.
176. Silver LL. The future of antibacterial discovery. **Clin Microbiol Rev**. 2020;33:e00113-19